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for the three countries were used in the model. The model focused on the initial
imaging, the need for further or confirmatory imaging and unnecessary or modifi-
cation of surgery. The model will be available as an iPad application during ISPOR.
RESULTS: Using PV-MRI resulted in increased certainty in the decision-making,
demonstrated by the reduced need for further imaging: 23.5% for MD-CT, 18.5% for
ECCM-MRI and 8.6% for PV-MRI. There was a need for confirmatory imaging in
high-risk surgery patients for 7.6% and 9% in the MD-CT and ECCM-MRI groups
respectively. Unnecessary surgery was performed in 3.4% of PV-MRI and 5.4% of
MD-CT and ECCM-MTI patients respectively. The need for intra-operative modifi-
cation of the surgical plan was 7.7% for PV-MRI, 10.5% for MD-CT and 10.3% for
ECCM-MRI. The cost of imaging, unnecessary and modified surgery was €892 for
MD-CT, €997 for ECCM-MRI and €888 for PV-MRI. Additionally, it was, as expected
more patients undergoing potential curative surgery in the PV-MRI group (49.4%
versus 47.6% for MD-CT and 45.4% for ECCM-MRI). CONCLUSIONS: Using PV-MRI
rather than ECCM-MRI and MD-CT for the initial imaging in patients with CRCLM
leads to expected cost savings and reduction of unnecessary and modified surgery.
A clinical trial, using a similar protocol as the model, is currently being analyzed.
The results of the trial will be used to further validate the modeling approach and
to demonstrate the impact on health outcomes.
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inadequate management of post-operative surgical wounds can lead to delayed
healing rates and complications, notably infection. Surgical site infections (SSI)
have been shown to extend hospital stay by an average of 14 days. OPSITE POST-OP
VISIBLE (Smith & Nephew) is a surgical film dressing that provides a waterproof,
breathable, bacteria barrier for surgical wounds and allows exudate management.
The visible nature of the dressing means that the wound area can be monitored
without removal of the dressing. OBJECTIVES: to compare the costs and outcomes
associated with the use of a surgical film dressing compared to standard treatment
in the management of post-operative surgical wounds. METHODS: An economic
evaluation was conducted alongside an open controlled trial conducted in 14 cen-
tres throughout Spain which compared a surgical film dressing to the standard
treatment with gauze dressings in the management of surgical wounds; 196 pa-
tients treated with gauze and 215 with a surgical film dressing. RESULTS: SSI rates
were significantly lower in patients treated with surgical film dressing compared to
gauze dressings (6,6% vs. 1.4%, p0,006). Patients treated with the surgical film
dressing experienced fewer blisters (8,7% vs. 2,3%, p0,004), erythemas (12,2% vs.
2,8%, p0,001) and weekly dressing changes (4,81 / 2,79 vs. 1,51 /0,87,
p0,001). CONCLUSIONS: The cost of a SSI in Spain is according with evidence
published €7,966 (2010 prices). The results produce a reduction in the average cost
of treating SSI of €438 per patient when treated with the surgical film dressing. The
incremental cost of treatment with the surgical film dressing during the post-
operative period is€5. It resulted in a significant average saving, even in a partial
analysis that considered only the costs associated with treating surgical site infec-
tions. The surgical film dressing provides a simple, inexpensive solution to the
costly problem of SSI.
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OBJECTIVES:To assess the costs savings of using an implantable loop recorder (ILR)
compared to current clinical practice in the diagnosis of AF for patients who had
suffered a first cryptogenic stroke, from the perspective of a Spanish hospital.
METHODS: We calculated the hospital resource utilization in the management of
patients after a first event. Based on the ILR sensitivity to diagnose AF in order to
avoid a second event, we assumed that patients with an ILR implanted won’t suffer
a second event while patients without will. Thereafter, we calculated the resource
utilization associated to the management of the second event. All resource utiliza-
tion such as hospitalization (stroke unit and neurology department), length of stay,
pharmacological treatment, tests and others were based on expert opinion. Costs
were expressed in Euro 2012. RESULTS: The cost per patient after a fist event was
€258 for the non-ILR strategy vs. €1,838 for the ILR, basically due to the cost of
implanting the device. A second event occurring only in the non-implanted pa-
tients will cost €7,418. Finally, overall treatment costs were €1,838 for the ILR strat-
egy compared to €7,675 for the non ILR strategy. Therefore, implanting ILR will save
up to €5,838 per patient per event avoided. CONCLUSIONS: The use of the Implant-
able Loop Recorder (Reveal© XT) in patients who had already suffered a first cryp-
togenic stroke leads to an earlier diagnosis of atrial fibrillation, avoiding potential
recurrences. Preventing a second event represents a cost-saving strategy due to the
avoidance of €5,838 per patient per event; therefore, it should be included in the
clinical management of patients with a first cryptogenic stroke.
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OBJECTIVES: To examine whether rapid PCR-based screening is a cost efficient tool
to optimize pre-emptive antibiotic therapy of methicillin resistant and methicillin
sensitive S. aureusinfections. METHODS: A decision analytic cost model was devel-
oped, based on data from peer-reviewed literature. Sensitivity analyses were un-
dertaken to investigate the impact of variation in MRSA rate, cost ratio of the cost
of appropriate antibiotic therapy to cost of inappropriate antibiotic therapy, PCR
test cost and total hospital costs per case. RESULTS: At the current MSRA-rate of
24.5 % in Germany, PCR-guided treatment regimens are cost-efficient compared to
empirical strategies. Costs of alternative treatment strategies differ, on average, up
to € 1780 per case. A pre-emptive MSSA-treatment strategy with PCR test is least
costly at lower rates of MRSA, while a pre-emptive MRSA-treatment strategy with
PCR testing is the least costly approach when the MRSA rate is greater than 53.7%.
An empirical MRSA-treatment strategy is least costly when the cost ratio is less
than 1.06. When the total hospital cost per MRSA-case is increased, pre-emptive
MSSA-treatment with PCR test achieves the lowest average cost, and the cost dif-
ference between the four treatment strategies increases. CONCLUSIONS: Early
verification and adaptation of an initial pre-emptive antibiotic treatment of S. au-
reus infections using PCR-based tests are advantageous in most situations to be
expected in Germany and other European countries. PCR tests accordingly should
be considered as elements in antimicrobial stewardship programs.
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OBJECTIVES: Atrial fibrillation (AF) is a chronic, progressive disease characterized
by uncoordinated atrial activation involving a rapid and irregular heartbeat (Fuster
et al., 2006). The prevalence of AF is1% in adults55 years old, but increases to as
much as 10% by age 80 (Go et al., 2001). The purpose of this study was to estimate
prevalence and economic burden in 2010 and forecast the prevalence and eco-
nomic burden of AF in 2015, 2020 and 2025 in selected countries. METHODS: The
prevalence and economic burden of AF in Belgium, Japan, The Netherlands, and
Spain was modeled based on prevalence rates identified via a literature search. The
prevalence and economic burden were forecasted based on 2010 estimates of AF
prevalence. Population forecasts for the selected countries were taken from United
Nations Department of Economic and Social Affairs forecasts. The adult population
was adjusted for the percentage of the population with access to health care. The
model assumed current age-adjusted prevalence rates would remain constant
through 2025. All costs are reported in 2011 euros. One-way sensitivity analysis was
performed for the health care accessible population and the country forecasted
population. RESULTS: In 2010, the prevalence and economic burden ranged from
77,700 and 236 million EUR in Belgium to 884,000 and 2.04 billion EUR in Japan. In
2025, the prevalence and economic burden ranged from 88,800 and 270 million EUR
in Belgium to 970,000 and 2.24 billion EUR in Japan. Sensitivity analyses revealed
that prevalence and economic burden were most affected by forecasted population
growth. CONCLUSIONS: The prevalence of AF in selected countries was forecasted
to grow substantially in both developing and developed countries. As the world’s
population ages and health care becomes more accessible, the economic burden of
AF will continue to rise as well.
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OBJECTIVES: Transient loss of consciousness (T-LOC) is characterised by rapid-
onset, short duration and spontaneous complete recovery. When the underlying
cause is cardiovascular, this event is known as syncope. Syncope is one of the most
common reasons for people attending the emergency department. Due to the rapid
onset of symptoms, syncope can lead to injuries and high costs. A database anal-
ysis was undertaken in five European countries to estimate the cost burden of
syncope. METHODS: Inpatient hospitalisation data were sourced from national
and local databases in France, Germany, the UK, Italy and Spain. Where possible,
the data were split according to whether syncope was the primary or secondary
diagnosis, to capture all cases in which syncope contributed to the hospitalisation.
DRG tariffs were then applied to each type of hospitalisation to estimate total costs
for each country for the period 2008-2011. RESULTS: When considering hospitali-
sations for which syncope was the primary diagnosis, annual costs per country
ranged from €90 million to €230 million (the total number of hospitalisations per
country ranged from 41,800 to 126,000). When all syncope-related hospitalisations
were considered, the annual figures per country ranged from €130 million to €305
million. In cases where syncope was a secondary diagnosis, the most common
reasons for hospitalisation were injuries to the head, pelvis and limbs. Within each
country, the results were consistent year-on-year. CONCLUSIONS: Syncope has a
significant cost burden which has been consistently observed across five major
European markets. These costs are only part of the overall burden, which also
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includes diagnosis and subsequent treatment. Whilst there are differences in the
results between countries due to coding practices and population, the results are
consistent over time and suggest a role for diagnostic interventions which can
speed up diagnosis, thus ensuring more appropriate patient management at an
earlier stage.
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OBJECTIVES: Atrial fibrillation (AF) is an arrhythmia that progressively worsens
and is characterized by uncoordinated atrial activation involving a rapid and irreg-
ular heart rate (Fuster et al., 2006). AF patients are likely to have concomitant
congestive heart failure (CHF) and stroke (Lee et al., 2008). The prevalence of AF in
adults 65 years is 5-6%, increasing with age (Go et al., 2001). The purpose of this
study was to estimate the economic burden of AF in selected developed countries
based on prevalence and direct health care costs.METHODS:The economic burden
of AF in Belgium, Japan, The Netherlands, and Spain was modeled based on prev-
alence rates identified via a literature search. Annual probabilities of receiving
health care treatment and associated costs for AF, stroke and CHF, and related
disability costs were included in the model. If cost data were unavailable, the costs
were imputed based on the ratio of annual per capita health expenditures between
the US and the country of interest. Cost estimates were calculated in 2011 euros.
RESULTS: The prevalence of AF in adults aged 65 in the countries studied was:
59,600 in Belgium; 83,400 in the Netherlands; 182,000 in Spain; and 593,400 in Japan.
The estimated annual economic burden of AF was: EUR 181.2 in Belgium; 256.6 in
the Netherlands; 333.5 in Spain; and 1,722.5 in Japan (in millions). CONCLUSIONS:
The economic burden of AF in developed countries is substantial, and is expected
to grow as the population ages. Early detection and appropriate management of AF
may help reduce this economic burden.
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OBJECTIVES: To evaluate the burden of SSI (surgery site infection) in common
surgeries in Korea. The considered surgeries: gastrointestinal surgery, Coronary
Artery Bypass Grafting (CABG) and orthopaedic surgery represent the procedures
with high, medium and low SSI risk. METHODS: The analysis was conducted from
the hospital perspective. Costs were evaluated on the basis of Health Insurance
Review Agency (HIRA) data. Risk of SSI and the influence of SSI on hospital length
of stay (LOS) were calculated according to studies from a review Lee 2011. The
influence of prolonged hospitalization on expenses was obtained with an assump-
tion that the costs are evenly distributed during the stay. RESULTS: The risk of SSI
depends on surgery type. Among the procedures considered, the highest SSI rate –
5% was related to gastric surgery and the lowest SSI rate – 1% to knee replacement.
LOS in case of SSI is prolonged for about 60%. According to current data on hospi-
talization cost from HIRA, the influence of SSI on providers’ budget could be sub-
stantial. The estimated increase in hospitalization cost induced by SSI is about 3.9
million won (2.700 €) for gastrointestinal surgery, 4.3 million won (3.000 €) for or-
thopaedic surgery and even 10.0 million won (6.900 €) for CABG. Halving the SSI rate
would reduce the mean expenses for about 1%. CONCLUSIONS: The burden of SSI
in Korea is high as SSI implies the significant prolongation of LOS. The detailed
analysis should then be carried out in order to define the possible ways of mini-
mizing the infection risk. The possible range of relatively non expensive risk-re-
ducing interventions which may imply the substantial reduction of SSI rate include
the use of antimicrobial sutures, antibiotics prophylactics, a safety checklist and
other. The increased cost of SSI prevention would be probably broadly offset by the
decreased costs of hospital stay.
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OBJECTIVES: To assess the cost of using continuous subcutaneous insulin infusion
(CSII) to treat children with diabetes and to compare it with the changes in HbA (1c)
and BMI. The study was performed from the point of view of the health insurance
fund and patients. METHODS: A combined retrospective and prospective analysis
of the patients’ records after the introduction of CSII was performed. Cost of CSII,
blood glucose monitoring system and strips was calculated. The primary outcome
observed was the variation in HbA(1c) and the secondary was the BMI change.
RESULTS: Subcutaneous insulin infusion (CSII) systems are of a limited usage be-
cause they are not reimbursed by the health insurance fund in the country. The
university pediatric clinic is introducing them on the request of the parents and
only 30 children apply such. 11 children with diabetes type 1 during the period
1999–2011 were observed (mean age 10 years, mean duration of the disease is 7
years, average usage of CSII - 3 years). The CSII price is 3896 Euro and compared to
the duration of usage it costs 1292 euro per patient per year. The blood glucose
monitoring system costs 20 Euro and for the duration of the disease - 4.96 Euro per
patient per year. The test stripes costs 533 Euro/ year (1100 stripes per year) and
their average cost according to the duration of the disease is 3779.45 Euro since
diagnosis. Thus the total yearly cost weighed with the duration of the disease is
1850 Euro (30% reimbursed). The average improvement of HbA (1c) after the CSII
introduction is 1.72 and the average BMI was 37.03. CONCLUSIONS: Improvements
in glycemic control associated with CSII led to reduced HbA(1c) that can guarantee
good diabetes management, but its control over BMI in growing children is still
unclear.
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OBJECTIVES: The frequency of newly diagnosed thyroid nodule is increasing, prob-
ably because of the widespread use of ultrasonography in Korea. However, there
are few researches about the incidence of thyroid cancer in patient with thyroid
nodules using national representative data. This study is performed to investigate
the incidence of thyroid cancer and medical costs among patients who were newly
diagnosed as thyroid nodule in South Korea. METHODS: We analyzed national
health claim database including all hospital records covering almost every popu-
lation by national health insurance system. We selected patients aged 20-120 years
old with thyroid nodules using ICD-10 codes of D34*, E041, E042 in 2008. We ex-
cluded all patients who were previously reported to have a thyroid nodule or any
type of cancer including thyroid cancer between 2006 and 2007. We conducted a
follow-up survey of the selected subjects on the national health claim database at
least for 2 years after diagnosis. RESULTS: We identified 283,844 eligible patients
with thyroid nodules. Their mean age 4813.2, and 234,388 (82.58%) subjects were
female. During median follow-up of 2.4 years, 21,538 (7.6%) Lower age, history of
thyroid disease or diabetes was associated with the risk of thyroid cancer. Mean
direct medical cost per patient paid by national insurer or shared by patient related
with newly diagnosis of thyroid nodules were about 475 Euros during follow up.
The medical cost of thyroid nodules subjects was 271 Euros, and it was especially
higher in patients with thyroidectomy (1378 Euros). CONCLUSIONS: In Korea, the
incidence of thyroid cancer was relatively higher, while the medical cost was much
lower than other countries, suggesting that careful follow-up for thyroid nodules
requited in Korea. Further study is needed to identify the risk factors of thyroid
cancer in patients with thyroid nodules.
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OBJECTIVES: Cervical degenerative disc disorders are increasingly common in
adults. Patients refractory to conservative therapy require surgery for relief of pain.
This micro-costing study sought to compare actual costs of index hospitalization
versus DRG revenue for cervical disc arthroplasty (CDA) in order to explore the
financial profit or loss of this emerging intervention for German hospitals.
METHODS:As published data is scarce, detailed in-hospital resource utilization for
1-level or 2-level CDA was mainly based on information supplied by three experi-
enced neurosurgeons from private and public German hospitals. Where available,
these estimates were compared and calibrated with existing data. Unit costs col-
lected from hospital accounting departments and information from German refer-
ence cost databases and the published literature were subsequently assigned to the
resource use items for the calculation of actual hospital costs associated with CDA.
RESULTS: Average total per-patient hospital costs were estimated at €5,930 for
1-level and €8,768 for 2-level arthroplasty. Most important cost drivers were the
costs of materials & disposables required for the intervention (relative contribution
to total hospital costs for 1-level CDA: 44%, for 2-level CDA: 58%), followed by
hospital ward costs (27%, 18%), use of operating and recovery room (15%, 13%),
OR-team (8%, 7%), and diagnostic examinations (6%, 4%). With current G-DRG pay-
ments for mono-segmental CDA (€6,620) and bi-segmental CDA (€9,815), German
hospitals can achieve average earnings of €690 (1-level CDA) and of €1,047 (2-level
CDA) when performing this emerging disc replacement technique.CONCLUSIONS:
Our costing study indicates that 1- or 2-level CDA represents a feasible and finan-
cially sustainable surgical therapy for German hospitals. First evidence from the
literature also tends to show that CDA is associated with additional long-term
benefits in terms of reduced rates of disc reoperations compared to conventional
anterior cervical discectomy and fusion.
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OBJECTIVES: To estimate the costs and benefits of diagnosis strategies using DNA
testing for mucinous pancreatic cysts (MPCs). METHODS: A decision tree was con-
structed that compared three diagnostic strategies for pancreatic cysts: 1) endo-
scopic ultrasound-guided fine needle aspiration (EUS-FNA) with cyst fluid testing
for carcinoembryonic antigen (CEA); 2) strategy 1DNA testing if insufficient fluid
for a CEA; 3) strategy 2DNA testing if the CEA is indeterminate. Probabilities of
insufficient fluid, positive, negative, and, indeterminate CEA results, and positive
DNA results given insufficient fluid or indeterminate results were calculated from
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